Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 13/20 | 0.66 |
| ▸ | DKK1 | O94907 | 2/20 | 0.60 |
| ▸ | GSK3B | P49841 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.51 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12275024 | 0.90 | IKBKB (0.58) | IKBKBDKK1GSK3BMAPK8JAK2 | |
| SCHEMBL1667153 | 0.87 | MEN1 (0.56) | IKBKBMEN1KMT2AJAK2 | |
| SCHEMBL14253957 | 0.86 | IKBKB (0.71) | IKBKBDKK1GSK3BMAPK8MAPK10 | |
| SCHEMBL3524407 | 0.86 | IKBKB (0.71) | IKBKBDKK1GSK3BMAPK8MAPK10 | |
| SCHEMBL3521925 | 0.86 | IKBKB (0.71) | IKBKBDKK1GSK3BMAPK8MAPK10 | |
| SCHEMBL12276011 | 0.84 | MEN1 (0.56) | GSK3BMEN1KMT2AJAK2 | |
| SCHEMBL12274689 | 0.84 | MEN1 (0.56) | IKBKBMEN1KMT2AJAK2 | |
| SCHEMBL12521628 | 0.84 | MEN1 (0.52) | IKBKBMEN1KMT2AJAK2 | |
| SCHEMBL12275119 | 0.84 | IKBKB (0.58) | IKBKBCHUK | |
| SCHEMBL12276240 | 0.83 | JAK2 (0.60) | IKBKBMEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2015-12-10 | — | — | US | disclosed |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | MYREXIS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352108-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON | TBK1, NFKBIA, CHUK | IKBKB 6/4885DKK1 3411/4885GSK3B 266/4885 |
| US-20120238540-A1 | AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1 | TBK1, NFKBIA, IKBKB | IKBKB 3/4885DKK1 2911/4885GSK3B 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.